Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies

회복기 및 예방접종을 받은 다발성 경화증 환자의 체액 및 세포 면역: 질병 변형 요법의 효과

Published on
Journal: Multiple sclerosis and related disorders
[저자] Mario Habek, Cvetić Željko, Ana Savić Mlakar, Krešo Bendelja, Dunja Rogić, Ivan Adamec, Barbara Barun, Tereza Gabelić, Magdalena Krbot Skorić
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,
PMC URL    [DOI] 10.1016/j.msard.2022.103682    
[Article Type] Article
[Source] PMC

Abstract
Objectives: To determine anti-SARS-Cov2 antibodies and T-cell immunity in convalescent people with multiple sclerosis (pwMS) and/or pwMS vaccinated against Covid-19, depending on the disease modifying therapy, and in comparison to healthy controls (HC).
Methods: 75 participants were enrolled: Group 1-29 (38.7%) COVID-19 convalescent participants; Group 2-34 (45.3%) COVID-19 vaccinated; Group 3-12 (16.0%) COVID-19 convalescent participants who were later vaccinated against COVID-19. Cellular immunity was evaluated by determination of number of CD4+ and CD8+ cells secreting TNFα, IFNγ, and IL2 after stimulation with SARS-CoV-2 peptides.
Results: pwMS treated with ocrelizumab were less likely to develop humoral immunity after COVID-19 recovery or vaccination. No difference was observed in the cellular immunity in all studied parameters between pwMS treated with ocrelizumab compared to HC or pwMS who were treatment naïve or on first line therapies. These findings were consistent in convalescent, vaccinated, and convalescent+vaccinated participants. COVID-19 vaccinated convalescent pwMS on ocrelizumab compared to COVID-19 convalescent HC who were vaccinated did not show statistically difference in the rate of seroconversion nor titers of SARS-CoV-2 antibodies.
Conclusion: Presence of cellular immunity in pwMS on B-cell depleting therapies is reassuring, as at least partial protection from more severe COVID-19 outcomes can be expected.
Keywords: Antibodies; B-cell depleting therapy; COVID-19; Multiple sclerosis; T-cell immunity.

All Keywords
【저자키워드】 COVID-19, antibodies, multiple sclerosis, T-cell immunity, B-cell depleting therapy, 【초록키워드】 Treatment, vaccination, therapy, severe COVID-19, Immunity, antibody, SARS-CoV-2 peptides, outcome, Humoral immunity, SARS-CoV-2 antibodies, cellular immunity, convalescent, group, Therapies, T-cell immunity, B-cell, Participants, healthy control, IFNγ, naïve, participant, TNFα, CD4+, Multiple, parameter, develop, the disease, evaluated, treated, less, determine, expected, depleting, secreting, IL2, statistically, CD8+ cell, Presence, rate of seroconversion, vaccinated against COVID-19, 【제목키워드】 therapy, cellular immunity, convalescent, disease, Effect,
{{{ 추상적인 }}} {{ 목표: }} 질병 변형 요법에 따라, 그리고 건강한 사람과 비교하여 Covid-19에 대한 예방접종을 받은 다발성 경화증(pwMS) 및/또는 pwMS가 있는 회복기의 사람들에서 항-SARS-Cov2 항체 및 T-세포 면역을 확인하기 위해 컨트롤(HC). {{ 방법: }} 75명의 참가자가 등록되었습니다: 그룹 1-29(38.7%) COVID-19 회복기 참가자; 그룹 2-34(45.3%) 그룹 3-12(16.0%) 나중에 COVID-19에 대한 예방접종을 받은 COVID-19 회복기 참가자. SARS-CoV-2 펩타이드로 자극한 후 TNFα, IFNγ 및 IL2를 분비하는 CD4+ 및 CD8+ 세포의 수를 측정하여 세포 면역을 평가했습니다. {{ 결과: }} ocrelizumab으로 치료한 pwMS는 COVID-19 회복 또는 백신 접종 후 체액성 면역이 발생할 가능성이 적었습니다. 치료 경험이 없거나 1차 요법을 받은 HC 또는 pwMS와 비교하여 ocrelizumab으로 치료한 pwMS 간에 연구된 모든 매개변수에서 세포 면역에 차이가 관찰되지 않았습니다. 이러한 결과는 회복기, 백신 접종 및 회복기+백신 접종 참가자에서 일관되었습니다. 백신을 접종한 COVID-19 회복기 HC와 비교하여 ocrelizumab에 대한 COVID-19 예방접종 회복기 pwMS는 혈청전환율이나 SARS-CoV-2 항체 역가에서 통계적으로 차이를 나타내지 않았습니다. {{ 결론: }} B-세포 고갈 요법에 대한 pwMS의 세포 면역의 존재는 더 심각한 COVID-19 결과로부터 적어도 부분적인 보호가 예상될 수 있기 때문에 안심할 수 있습니다. {{ 키워드: }} 항체; B 세포 고갈 요법; 코로나바이러스감염증-19 : 코로나19; 다발성 경화증; T 세포 면역.